Related Experiment Video
Updated: Aug 9, 2026

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
Published on: August 14, 2019
Metabolic factors associated with benign prostatic hyperplasia
J Kellogg Parsons1, H Ballentine Carter, Alan W Partin
1Division of Urology, University of California San Diego, 200 West Arbor Drive, San Diego, California 21287, USA. k0parsons@ucsd.edu
Context:
Benign prostatic hyperplasia poses a significant public health problem, but its etiology remains unclear. Obesity and associated abnormalities in glucose homeostasis may play a role in benign prostatic hyperplasia development by influencing prostate growth.
Objective:
The objective of this study was to determine whether obesity, fasting plasma glucose concentration, and diabetes are associated with radiologically determined prostate enlargement, an objective measure of benign prostatic hyperplasia.
Design:
This study was a cross-sectional analysis with robust variance estimates to account for multiple measures over time in the same individuals.
Setting:
This prospective cohort study was composed of community volunteers.
Patients:
Patients studied were 422 adult men enrolled in The Baltimore Longitudinal Study of Aging.
Main Outcome Measurements:
Total prostate volume as determined by pelvic magnetic resonance imaging was measured.
Results:
Among 422 participants, 91 (21.6%) had prostate enlargement (defined as total prostate volume >/= 40 cc) at first visit. Compared with men of normal weight [body mass index (BMI) < 25 kg/m(2)], the age-adjusted odds ratio (OR) for prostate enlargement for overweight men (BMI, 25-29.9 kg/m(2)) was 1.41 (95% CI, 0.84-2.37), for obese men (BMI, 30-34 kg/m(2)) was 1.27 (95% CI, 0.68-2.39), and for severely obese men (BMI >/= 35 kg/m(2)) was 3.52 (95% CI, 1.45-8.56) (P = 0.01). Men with elevated fasting glucose (>110 mg/dl) were more likely to have an enlarged prostate than men with normal fasting glucose (=110 mg/dl) (OR, 2.98; 95% CI, 1.70-5.23), as were men with a diagnosis of diabetes (OR, 2.25; 95% CI, 1.23-4.11).
Conclusions:
Obesity, elevated fasting plasma glucose, and diabetes are risk factors for benign prostatic hyperplasia.
Related Concept Videos
Factors Affecting Drug Biotransformation: Physicochemical and Chemical Properties of Drugs
The drug's acidity or basicity is essential in determining the metabolic...
Factors Affecting Drug Biotransformation: Biological
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Metabolic Rate
The Basal Metabolic Rate (BMR) measures the energy expended at rest.
Several factors influence the...
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
